About this trial
The goal of this survey is to assess several aspects related to patient preferences regarding interventions for alleviating tinnitus through invasive electrical brain stimulation (neuromodulation). This survey covers the acceptance of a surgically-placed brain implant, of its associated risks related to the neurosurgical procedure, usability considerations, and the willingness/ability to pay for such a treatment.
Neurosoft Bioelectronics will use the collected patients' feedback and usability preferences data for the development of a novel minimally invasive brain implant aimed at alleviating tinnitus.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Individuals aged 18 or older suffering from subjective tinnitus
Self-reported or healthcare professional-diagnosed chronic (lasting 3 months or longer), subjective, burdensome tinnitus
Disqualifiers
Individuals under 18 years of age
Healthy volunteers without tinnitus
Trial population
Adult patients (over 18 years old) with chronic, subjective severe tinnitus
Trial design
Other
Prospective
Treatments tested in this trial
Survey using a questionnaire.
Other interventionpatients preferences survey
Treatment groups
Trial outcomes
Primary outcomes
Acceptance of invasive neuromodulation treatments for chronic tinnitus
Risks acceptance and user preferences will be assessed through responses to the survey. The outcome will be summarized in the form of a percentage or similar statistics on acceptances rates for surgical interventions in patients with chronic tinnitus. Acceptance rates will also be evaluated in accordance to several clinical characteristics of tinnitus, such as its perceived annoyance or loudness.
Secondary outcomes
Usability preferences for implantable neuromodulation systems for chronic tinnitus
Usability preferences will be assessed through responses to the survey. This secondary outcome will be summarized in the form of a percentage or similar statistics on usability preferences between different solutions involving surgical interventions in patients with chronic tinnitus. Usability preferences will also be evaluated with respect to different reported tinnitus characteristics, such as perceived annoyance or loudness.
Willingness and ability to pay for novel invasive neuromodulation solutions for chronic tinnitus
Willingness to pay (WTP) will be assessed through responses to the survey. This secondary outcome will be summarized in the form of a range ($ US) or similar statistics on willingness and ability to pay with respect to different solutions involving surgical interventions in patients with chronic tinnitus. WTP will also be evaluated with respect to different reported tinnitus characteristics, such as perceived annoyance or loudness.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Nicolas Gninenko
Lead sponsor
Neurosoft Bioelectronics SA
Sponsor institution